Washington, D.C. – Today, the Centers for Disease Control and Prevention (CDC) released a Morbidity and Mortality Weekly Report (MMWR) titled Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance —The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014 which is the first report to present comprehensive data from CDC’s gonorrhea surveillance system and summarize gonorrhea resistance trends over time. What this report outlines is deeply troubling: resistance levels of gonorrhea to azithromycin, one of the two drugs in the recommended dual therapy treatment for gonorrhea, increased from 0.6 percent in 2013 to 2.5 percent in 2014. This is a 316 percent increase in just one year. Read the full article here.
Recent Rapid Developing Gonorrhea Resistance Raises Grave Concerns About Controlling this Epidemic